Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Nutritional Influences on the Brain in ADHD: Evidence from Neuroimaging Studies.

Neurology international·2026

Same author

Divergent modulation of dopaminergic neurons by hypocretin/orexin receptors-1 and -2 shapes dopaminergic cell activity and socio-emotional behavior.

Biological psychiatry·2026

Same author

Frequency- and Network-Specific Changes in Functional Connectivity Reflect Pathophysiological Mechanisms across Parkinson's Disease Stages.

Annals of neurology·2026

Same author

Cell Cycle Dysfunction and Metabolic Alterations Consistent With Pathological Tau in Progressive Supranuclear Palsy Derived Fibroblasts.

Molecular neurobiology·2026

Same author

Developmental and cell type-specific contributions of thalamic serotonin 2A receptors to absence seizures.

Epilepsia·2026

Search research articles

Related Experiment Video

Updated: Dec 23, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Acute and Chronic Dopaminergic Depletion Differently Affect Motor Thalamic Function.

Giuseppe Di Giovanni^1,2, Laura Clara Grandi³, Ernesto Fedele^4,5

¹Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida MSD 2080, Malta.

International Journal of Molecular Sciences

|April 25, 2020

Summary

Dopamine depletion impacts motor thalamus function differently in acute versus chronic states. Chronic dopamine loss in the motor thalamus rebalances neurotransmitters, counteracting acute depletion effects.

Keywords:

L-DOPA deep brain stimulation electrophysiology immunohistochemistry microdialysis

More Related Videos

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

Related Experiment Videos

Last Updated: Dec 23, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

Area of Science:

Neuroscience
Motor Control
Neuropharmacology

Background:

The motor thalamus (MTh) is integral to the basal ganglia-cortical motor loop.
Its function in normal and Parkinsonian states remains under-investigated.

Purpose of the Study:

To investigate motor thalamus neuronal activity, cortical interplay, and neurotransmitter levels under acute and chronic dopamine depletion.
To elucidate the functional adaptations of the MTh in response to dopamine loss.

Main Methods:

Examined MTh neuronal firing, cortical/MTh coupling, and extracellular glutamate (GLU) and GABA concentrations in rats.
Utilized acute tetrodotoxin (TTX) and chronic 6-hydroxydopamine (6-OHDA) to induce dopamine depletion in the medial forebrain bundle (MFB).

Main Results:

Acute TTX depletion reduced MTh neuronal activity but not burst firing; chronic 6-OHDA depletion increased burst firing without altering overall rate.
Chronic 6-OHDA altered MTh-cortical coupling compared to acute TTX.
Acute TTX increased MTh GABA; chronic 6-OHDA decreased GABA and increased GLU.

Conclusions:

The motor thalamus is significantly affected by dopamine depletion.
Chronic dopamine depletion appears to induce compensatory rebalancing of neurotransmitters (GABA/GLU) in the MTh, counteracting acute depletion effects.